What is it and what does it include?
This was a Phase III trial that enrolled 1461 participants of ages 51 or older with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672 prior to enrollment. All subjects received rosiglitazone extended release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR as adjunctive therapy to their existing dose of acetylcholinesterase inhibitor. This study also explored further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.
How can I use this dataset to advance my research?
This dataset is ideal if:
- you’re studying PPAR-γ agonists efficacy for the improvement of cognitive function in human models.
Has this dataset helped researchers understand Alzheimer’s and other dementias better?
Of course!
- AD & Pharmacokinetics:
In 2011, researchers found no evidence of statistically or clinically significant efficacy in cognition or global function for 2 mg or 8 mg RSG XR as adjunctive therapy to ongoing AChEIs (Acetylcholine esterase inhibitors) therapy. There was no evidence of an interaction between treatment and APOE status. Safety and tolerability of RSG XR was consistent with the known profile of rosiglitazone. April 2011 – DOI: 10.2174/156720511796391935
